A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancer
The cysteine-rich epidermal growth factor ligand domain 2 protein (CRELD2) is associated with pathways that regulate epithelial-to-mesenchymal transition, a critical process driving cancer metastasis. This study aimed to determine the prognostic value of CRELD2 status on survival outcomes in triple...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2025-01-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://bjbms.org/ojs/index.php/bjbms/article/view/11865 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542695938064384 |
|---|---|
| author | Mehmet Zahid Kocak Murat Araz Siddika Findik Aykut Demirkiran Mustafa Korkmaz Melek Karakurt Eryilmaz Mehmet Artac |
| author_facet | Mehmet Zahid Kocak Murat Araz Siddika Findik Aykut Demirkiran Mustafa Korkmaz Melek Karakurt Eryilmaz Mehmet Artac |
| author_sort | Mehmet Zahid Kocak |
| collection | DOAJ |
| description |
The cysteine-rich epidermal growth factor ligand domain 2 protein (CRELD2) is associated with pathways that regulate epithelial-to-mesenchymal transition, a critical process driving cancer metastasis. This study aimed to determine the prognostic value of CRELD2 status on survival outcomes in triple-negative breast cancer (TNBC). Seventy patients were included in the study. Thirty-four patients were metastatic, and 36 patients were non-metastatic. CRELD2 protein expression in tumor tissue was determined by immunohistochemical staining (IHC). The patients were divided into two groups: CRELD2 positive and negative groups. Clinicopathological features and survival outcomes were compared between the groups. In the survival analysis of the non-metastatic patient group, five-year overall survival (OS) rate was 91.7% in the CRELD2-positive patient group and 91% in the negative group (P = 0.91). Median progression free survival (PFS) was 9.4 (95% confidence interval [CI]: 6.4–12.4) months in the CRELD2-positive group and 11.9 (95% CI: 8.2–18.6) months in the CRELD2-negative group (P = 0.04). The median OS was 17.2 (95% CI: 13.7–22.3) months in the CRELD2-positive group and 24.7 (95% CI: 21.8–29.6) months in the CRELD2-negative group (P = 0.02). In multivariate analysis, CRELD2 status (negative vs positive) (hazard ratio [HR]: 0.50, 95% CI: 0.38–0.96, P = 0.02) was determined to be a risk factor for OS and CRELD2 status (negative vs positive) (HR: 0.82, 95% CI: 0.33–0.96, P = 0.01) was defined as a risk factor for PFS in patients with metastatic TNBC. This is the first clinical study to determine the effect of CRELD2 on survival and as a prognostic marker in patients with triple metastatic breast cancer. These results need to be validated prospectively with a large sample size.
|
| format | Article |
| id | doaj-art-03cdbfa5c0444412bdb6e713176fc101 |
| institution | Kabale University |
| issn | 2831-0896 2831-090X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | Article |
| series | Biomolecules & Biomedicine |
| spelling | doaj-art-03cdbfa5c0444412bdb6e713176fc1012025-02-03T16:42:09ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2025-01-0110.17305/bb.2024.11865A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancerMehmet Zahid Kocak0https://orcid.org/0000-0003-3085-7964Murat Araz1https://orcid.org/0000-0002-4632-9501Siddika Findik2https://orcid.org/0000-0002-3364-7498Aykut Demirkiran3Mustafa Korkmaz4Melek Karakurt Eryilmaz5Mehmet Artac6Necmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, TurkeyNecmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, TurkeyNecmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Pathology, Konya, TurkeyNecmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, TurkeyNecmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, TurkeyNecmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, TurkeyNecmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, Turkey The cysteine-rich epidermal growth factor ligand domain 2 protein (CRELD2) is associated with pathways that regulate epithelial-to-mesenchymal transition, a critical process driving cancer metastasis. This study aimed to determine the prognostic value of CRELD2 status on survival outcomes in triple-negative breast cancer (TNBC). Seventy patients were included in the study. Thirty-four patients were metastatic, and 36 patients were non-metastatic. CRELD2 protein expression in tumor tissue was determined by immunohistochemical staining (IHC). The patients were divided into two groups: CRELD2 positive and negative groups. Clinicopathological features and survival outcomes were compared between the groups. In the survival analysis of the non-metastatic patient group, five-year overall survival (OS) rate was 91.7% in the CRELD2-positive patient group and 91% in the negative group (P = 0.91). Median progression free survival (PFS) was 9.4 (95% confidence interval [CI]: 6.4–12.4) months in the CRELD2-positive group and 11.9 (95% CI: 8.2–18.6) months in the CRELD2-negative group (P = 0.04). The median OS was 17.2 (95% CI: 13.7–22.3) months in the CRELD2-positive group and 24.7 (95% CI: 21.8–29.6) months in the CRELD2-negative group (P = 0.02). In multivariate analysis, CRELD2 status (negative vs positive) (hazard ratio [HR]: 0.50, 95% CI: 0.38–0.96, P = 0.02) was determined to be a risk factor for OS and CRELD2 status (negative vs positive) (HR: 0.82, 95% CI: 0.33–0.96, P = 0.01) was defined as a risk factor for PFS in patients with metastatic TNBC. This is the first clinical study to determine the effect of CRELD2 on survival and as a prognostic marker in patients with triple metastatic breast cancer. These results need to be validated prospectively with a large sample size. https://bjbms.org/ojs/index.php/bjbms/article/view/11865Cysteine-rich epidermal growth factor ligand domain 2 proteinCRELD-2breast cancertriple negativesurvival |
| spellingShingle | Mehmet Zahid Kocak Murat Araz Siddika Findik Aykut Demirkiran Mustafa Korkmaz Melek Karakurt Eryilmaz Mehmet Artac A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancer Biomolecules & Biomedicine Cysteine-rich epidermal growth factor ligand domain 2 protein CRELD-2 breast cancer triple negative survival |
| title | A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancer |
| title_full | A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancer |
| title_fullStr | A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancer |
| title_full_unstemmed | A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancer |
| title_short | A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancer |
| title_sort | preliminary study on the prognostic significance of cysteine rich egf ligand domain 2 protein creld2 in patients with triple negative breast cancer |
| topic | Cysteine-rich epidermal growth factor ligand domain 2 protein CRELD-2 breast cancer triple negative survival |
| url | https://bjbms.org/ojs/index.php/bjbms/article/view/11865 |
| work_keys_str_mv | AT mehmetzahidkocak apreliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer AT murataraz apreliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer AT siddikafindik apreliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer AT aykutdemirkiran apreliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer AT mustafakorkmaz apreliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer AT melekkarakurteryilmaz apreliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer AT mehmetartac apreliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer AT mehmetzahidkocak preliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer AT murataraz preliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer AT siddikafindik preliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer AT aykutdemirkiran preliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer AT mustafakorkmaz preliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer AT melekkarakurteryilmaz preliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer AT mehmetartac preliminarystudyontheprognosticsignificanceofcysteinerichegfliganddomain2proteincreld2inpatientswithtriplenegativebreastcancer |